Closed · opens Mon 9:30 AM ET
The Marked Chart Wire · Health
Gilead
Gilead Sciences stated that emvistegrast 200 mg achieved the main objective in a second-stage dose-ranging trial. The drug showed notable differences in secondary disease-activity measures, and the firm intends to launch a third-stage monotherapy study in 2027.
BioNTech Gilead
BioNTech and Gilead Sciences will run a clinical trial combining pumitamig with sacituzumab govitecan. BioNTech and Bristol Myers Squibb are co-developing the investigational drug pumitamig.
CRISPR Therapeutics
CRISPR Therapeutics' pipeline candidate CTX310 is viewed as having a larger market opportunity than its approved product Casgevy.
Nubeqa
Orion Corporation stated that adding Nubeqa to standard care significantly lowered the chance of disease spread or mortality in high-risk patients.
Lung Cancer
Amgen reported that adding its medication to AstraZeneca’s immunotherapy reduced the chance of death by 58 percent for individuals with advanced lung tumors.
Cancer Vaccine
The two companies disclosed late-stage clinical findings for their mRNA therapy, intismeran autogene, after an information leak occurred.
AbbVie
The FDA approved an injectable version of AbbVie's Skyrizi to treat moderate to severe Crohn's disease.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.